Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2 Study to Evaluate Antibody-Drug Conjugate Sacituzumab Govitecan in Combination With PARP Inhibitor Talazoparib in Patients With Metastatic Breast Cancer

NCT04039230 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT04039230
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04039230 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2 Study to Evaluate Antibody-Drug Conjugate Sacituzumab Govitecan in Combination With PARP Inhibitor Talazoparib in Patients With Metastatic Breast Cancer
Lead sponsor
Massachusetts General Hospital
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
October 9, 2019
Completion date
January 31, 2029
Enrollment
75 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer